Co-Authors
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and GARY E GALLICK.
Connection Strength
1.469
-
Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers (Basel). 2020 Jan 19; 12(1).
Score: 0.179
-
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
Score: 0.178
-
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21.
Score: 0.131
-
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013 Aug; 3(8):849-61.
Score: 0.113
-
Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 2013 Oct 01; 133(7):1536-46.
Score: 0.112
-
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 2013 Jun; 73(9):979-85.
Score: 0.110
-
Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One. 2012; 7(12):e51189.
Score: 0.109
-
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 2011 Dec; 20(12):1677-84.
Score: 0.101
-
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One. 2009 Aug 04; 4(8):e6511.
Score: 0.086
-
Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. iScience. 2021 Apr 23; 24(4):102388.
Score: 0.049
-
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264.
Score: 0.048
-
Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell. 2017 06 05; 41(5):467-480.e3.
Score: 0.037
-
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017 May 23; 10(480).
Score: 0.037
-
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer. 2016 09 06; 16:721.
Score: 0.035
-
Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res. 2015 Nov 15; 75(22):4949-59.
Score: 0.033
-
Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics. 2015 Mar; 14(3):471-83.
Score: 0.031
-
Targeting constitutively activated ?1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013 Apr; 11(4):405-17.
Score: 0.027
-
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011 Nov 16; 103(22):1665-75.
Score: 0.025
-
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 01; 118(1):63-71.
Score: 0.025